Effect of statins on development of early cognitive dysfunction after coronary artery bypass grafting

Kardiologiya

Volumn 55, Issue 4, 2015, Pages 49-56

  Trubnikova, O A ^a   Maleva, O V ^a   Tarasova, I V ^a   Mamontova, A S ^a   Uchasova, E G ^a   Barbarash, O L ^a  

^a RESEARCH INSTITUTE FOR COMPLEX ISSUES OF CARDIOVASCULAR DISEASES   (Russian Federation)

Author keywords

CABG; Early postoperative cognitive decline; Interleukins; Rosuvastatin; Systemic inflammatory response

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN DERIVATIVE; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

BLOOD; CHEMOPROPHYLAXIS; COGNITION; COGNITION DISORDERS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; PROCEDURES; PROGNOSIS;

C-REACTIVE PROTEIN; CHEMOPREVENTION; COGNITION; COGNITION DISORDERS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKINS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; PROGNOSIS; ROSUVASTATIN CALCIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934284834     PISSN: 00229040     EISSN: 24125660     Source Type: Journal    
DOI: 10.18565/cardio.2015.4.49-56     Document Type: Article

References (34)

1. Silbert B.S., Maruff P., Evered L.A., Scott D.A., Kalpokas M., Martin K.J., Lewis M.S., Myles P.S. Detection of cognitive decline after coronary surgery: a comparison of computerized and conventional tests. Bri. J Anaesthesia 2004;92:814-820.
2. Buziashvili Yu. I., Ambat'ello S. G., Aleksakhina Iu. A., Pashchenkov M.V. Influence of cardiopulmonary bypass on cognitive functions in patients with ischemic heart disease. Zhumal nevrologii i psikhiatrii imeni S.S. Korsakova 2005;105(1):30-35.
3. Sweet J.J., Finnin E., Wolfe P.L., Beaumont J.L., Hahn E., Marymont J., Sanborn T., Rosengart T.K. Absence of cognitive decline one year after coronary bypass surgery: comparison to nonsurgical and healthy controls. Ann Thorac Surg 2008;85:1571-1578.
4. Hudetz J.A., Patterson K.M., Byrne A.J. Pagel P.S., Warltier D.C. Postoperative delirium is associated with postoperative cognitive dysfunction at one week after cardiac surgery with cardiopulmonary bypass. Psychol Rep 2009;105:921-932.
5. Bokeriia L.A., Merzliakov V. Ju., Kliuchnikov I.V., Skopin A. I., Mamedova S.K., Melikulov A. A. Long-term results and life-quality in patients after mini-invasive myocardial revascularization (survey of literature). Bjul NCSSH im. A.N. Bakuleva RAMN 2009;5:9-16.
6. Postnov V.G., Karas'kov A.M., Lomivorotov V.V. Neurologic aspects of cardiac surgery: guidelines for physicians. Novosibirsk: Sibregion info 2007; 255 p.
7. Dement'eva I.I., Sandrikov V.A., Morozov Ju.A., Charnaja M.A., Morozov Ju.A., Goncharova A.V., Fedulova S.V. Problem of cerebral microembolism complications in cardiac surgery patients and hemoreologic methods of their prevention. Patol krovoobr i kardiohir 2010; 3: 50-55).
8. Seines O.A., Gottesman R.F., Grega M.A., Baumgartner W.A., Zeger S.L., McKhann G.M. Cognitive and neurologic outcomes after coronary-artery bypass surgery. N Engl J Med 2012;366:250-257.
9. Pavlik V.N., Alves de Moraes S., Szklo M., Knopman D.S., Mosley TH Jr., Hyman D.J. Relation between cognitive function and mortality in middle-aged adults: the atherosclerosis risk in communities study. Am J Epidemiol 2003; 157:327-334.
10. Damulin I.V. Cognitive and motor disorders in vascular encephalopathy and vascular dementia. Vrach 2005;11:3-6.
11. Levin O.S. Diagnosis and treatment of dementia in clinical practice. M.: MEDPRESS-inform 2010; 256 p.
12. Pasquier F. Diabetes and cognitive impairment: how to evaluate the cognitive status? Diabetes Metab 2010;36:100-105.
13. Kozlov V.K. Immunopathogenesis and cytokine therapy for surgical sepsis. Posobie dlja vrachej. St-Peterburg: Jasnyj Svet 2002;48.
14. Eremenko A.A., Zjudjaeva T.P., Egorov Ja.V. Sidorenko Ya.V., Fominykh M.V. Influence of Mexidol on systemic inflammation reaction at the patients undergoing myocardial revascularization surgery with artificial circulation. Kardiol i serdechno-sosudistaja hir 2008;1:67-72.
15. Ray K.K., Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005;46:1425-1433.
16. Chello M., Anselmi A., Spadaccio C, Patti G., Goffredo C., Di Sciascio G., Covino E. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg 2007;83:1374-1380.
17. O'Neil-Callahan K., Katsimaglis G., Tepper M.R., Ryan J., Mosby C, Ioannidis J.P., Danias P.G. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. J Am Coll Cardiol 2005;45:336-342.
18. Radaelli A., Loardi C, Cazzaniga M., Balestri G., DeCarlini C., Cerrito M.G., Cusa E.N., Guerra L., Garducci S., Santo D., Menicanti L., Paolini G., Azzellino A., Lavitrano M.L., Mancia G., Ferrari A.U. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination. Arterioscler Thromb Vasc Biol 2007;27:2750-2755.
19. Barbarash O.L., Bajrakova JuV., Kurguzova E.M. Preoperative statin therapy in patients with ischemic heart disease. Kardiosomatika 2011;2:51-54.
20. Aboyans V., Labrousse L., Lacroix P., Guilloux J., Sekkal S., Le Guyader A., Cornu E., Laskar M. Predictive factors of stroke in patients undergoing coronary bypass grafting: statins are protective. Eur J Cardiothorac Surg 2006;30:300-304.
21. Katznelson R., Djaiani G.N., Borger M.A., Friedman Z., Abbey S.E., Fedorko L., Karski J., Mitsakakis N., Carroll J., Beattie W.S. Preoperative use of statins is associated with reduced early delirium rates after cardiac surgery. Anesthesiology 2009; 110:67-73.
22. Ivanov V.I., Litvinova N.A., Berezina M.G. Automated complex for individual assessment of individual and typological characteristics and functional state of the human body «STATUS PF». Valeologija 2004;4:70-73.
23. Pinon P., Kaski J.C. Inflammation, atherosclerosis and cardiovascular disease risk. Rev Esp Cardiol 2006;59:247-258.
24. Ebersoldt M., Sharshar T., Annane D. Sepsis-associated delirium. Intensive Care Med 2007;33:941-950.
25. Semmler A., Hermann S., Mormann F., Weberpals M., Paxian S.A., Okulla T., Schäfers M., Kummer M.P., Klockgether T., Heneka M.T. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation 2008;5:38.
26. Morandi A., Hughes CG, Girard T.D., McAuley D.F., Ely E.W., Pandharipande P.P. Statins and brain dysfunction: a hypothesis to reduce the burden of cognitive impairment in patients who are critically ill. Chest 2011;140:580-585.
27. Perry V.H., Nicoll J.A, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193-201.
28. Hedman A., Larsson P.T., Alam M., Wallen N.H., Nordlander R., Samad B.A. CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events? Int J Cardiol 2007;9:108-114.
29. van Gool W.A., van de Beek D., Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 2010;375: 773-775.
30. de Mendonça-Filho H., Pereira K., Fontes M., Vieira D.A., de Mendonça M.L., Campos L.A., Castro-Faria-Neto H.C. Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: a prospective observational study. Crit Care 2006; 10:R46.
31. Domoki F., Kis B., Gáspár T., Snipes J.A., Parks J.S., Bari F., Busija D.W. Rosuvastatin induces delayed preconditioning against L-glutamate excitotoxicity in cultured cortical neurons. Neurochem Int 2010;56:404-409.
32. Savoia G, Sisalli M.J., Di Renzo G., Annunziato L., Scorziello A. Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. Int J Physiol Pathophysiol Pharmacol 2011;3: 57-64.
33. Ballantyne CM., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008;52:626-632.
34. Miller P.S., Smith D.G., Jones P. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Am J Cardiol 2005;95: 1314-1319.